• to decrease the potential risk of critical cardiovascular (heart and blood vessel) challenges in Older people with variety 2 diabetes and heart problems In Oct 2024, Novo Nordisk published a research on scientific journal Nature about a novel glucose-delicate insulin NNC2215 that could